Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Position Increased by Crestline Management LP

Crestline Management LP lifted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 66.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 713,205 shares of the company's stock after buying an additional 284,667 shares during the quarter. Crestline Management LP owned about 0.84% of Syndax Pharmaceuticals worth $9,429,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new stake in Syndax Pharmaceuticals during the fourth quarter worth approximately $26,000. Virtus ETF Advisers LLC grew its holdings in shares of Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after purchasing an additional 827 shares in the last quarter. Cape Investment Advisory Inc. lifted its position in Syndax Pharmaceuticals by 157.1% in the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock worth $85,000 after purchasing an additional 3,927 shares during the period. KBC Group NV boosted its position in shares of Syndax Pharmaceuticals by 104.8% during the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock valued at $92,000 after acquiring an additional 3,559 shares in the last quarter. Finally, Optimize Financial Inc bought a new stake in Syndax Pharmaceuticals in the fourth quarter valued at about $152,000.

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock opened at $13.57 on Tuesday. Syndax Pharmaceuticals, Inc. has a one year low of $9.66 and a one year high of $25.07. The stock's 50-day moving average is $12.85 and its 200-day moving average is $14.59. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -3.74 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.24) by $0.26. Syndax Pharmaceuticals's revenue for the quarter was up 1900.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.85) earnings per share. On average, equities analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Insider Buying and Selling at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, insider Neil Gallagher sold 4,618 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares of the company's stock, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,683 shares of company stock valued at $336,087 in the last quarter. Company insiders own 4.10% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SNDX. HC Wainwright reiterated a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Citigroup decreased their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. Scotiabank lowered their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. JPMorgan Chase & Co. increased their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. Finally, StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $36.20.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.